Feb 19, 2019
The agreement enables early access to the MiCheck® Prostate Cancer Test for US Clinicians & Patients
Oct 03, 2018
Demerger clears the path for therapeutic company capital raising
Sep 04, 2018
Minomic has received a Notice of Allowance for the company's patent covering its cell surface antigen for the diagnosis of prostate cancer
Jul 29, 2018
Minomic completed enrolment and dosing of all 12 patients in its pioneering clinical trial of Miltuximab®, a chimeric version of Minomic's MIL-38 anti-Glypican 1 antibody conjugated to the radioactive isotope 67Gallium.
May 17, 2018
MiCheck® demonstrated competitive sensitivity and specificity in both identification of prostate cancer and differentiating aggressive from non-aggressive cancer in a recently completed prospective clinical trial
Jul 17, 2017
Novel prostate cancer screening technology targeting commercialization in 2017 Verification of test accuracy and reliability for CLIA lab access
Jun 28, 2017
Drug Safety Monitoring Committee Approval to Proceed to Final Six Patients of Twelve. First-in-human trial on safety and tolerability passes key stage-gate.